Recombinant Mouse Endostatin (C-6His)
- Cat. No.：EPT193
- Price：Negotiable
- Clicks：1438
Product Detail
Basic Information
| Size | 10ug |
|---|
| Expression Host | Human Cells |
|---|
| Tag | C-6His |
|---|
Physical Properties
| Molecular Weight | 21.2 KDa |
|---|
| Apparent Molecular Weight | 18 KDa, reducing conditions |
|---|
| Form | Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4. |
|---|
| Purity | Greater than 95% as determined by reducing SDS-PAGE. |
|---|
Activity & Endotoxin
| Endotoxin Level | Less than 0.1 ng/µg (1 EU/µg) as determined by LAL test. |
|---|
Storage & Shipping
| Reconstitution | Always centrifuge tubes before opening.Do not mix by vortex or pipetting.
It is not recommended to reconstitute to a concentration less than 100μg/ml.
Dissolve the lyophilized protein in distilled water.
Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
|---|
| Storage | Lyophilized protein should be stored at < -20°C, though stable at room temperature for 3 weeks.
Reconstituted protein solution can be stored at 4-7°C for 2-7 days.
Aliquots of reconstituted samples are stable at < -20°C for 3 months. |
|---|
| Shipping Condition | The product is shipped at ambient temperature.
Upon receipt, store it immediately at the temperature listed below. |
|---|
Detailed Description
| Background | Endostatin, an endogenous non‑glycosylated inhibitor of endothelial cell proliferation and angiogenesis. It is produced and/or trimmed by metalloproteinases such as MMP‑2 and MMP‑9, and cathepsins S, B and L. The N‑terminal ~27 aa of Endostatin appear to contain the majority of its activity. This region contains zinc binding sites that are thought to be critical for its anti‑endothelial and anti‑tumor effects, as well as multiple cleavage sites that, when used, can modify its activity. Mouse Endostatin shares 96% aa sequence identity with rat and 85‑87% with human, bovine and equine Endostatin. It is predominantly expressed in liver, kidney, lung, skeletal muscle and testis. Endostatin inhibits endothelial cell growth by inducing cell cycle arrest in G1 phase and initiating apoptosis. It is also thought to down‑regulate angiogenesis by blocking VEGF‑induced endothelial cell migration. Endostatin may also be involved with down‑regulation of angiogenesis after establishment of placental circulation in the pregnant uterus. |
|---|
